Continuous recording of vital signs with a wearable device in pediatric patients undergoing chemotherapy for cancer-an operational feasibility study

Christa Koenig, Roland A Ammann, Claudia E Kuehni, Jochen Roessler, Eva Brack, Christa Koenig, Roland A Ammann, Claudia E Kuehni, Jochen Roessler, Eva Brack

Abstract

Purpose: Pediatric patients with cancer are at high risk for severe infections. Infections can trigger changes of vital signs long before clinical symptoms arise. Continuous recording may detect such changes earlier than discrete measurements. We aimed to assess the feasibility of continuous recording of vital signs by a wearable device (WD) in pediatric patients undergoing chemotherapy for cancer.

Methods: In this prospective, observational single-center study, pediatric patients under chemotherapy wore the Everion® WD for 14 days. The predefined patient-specific goal was heart rate recorded in good quality during ≥18/24 h per day, on ≥7 consecutive days. The predefined criterion to claim feasibility was ≥15/20 patients fulfilling this patient-specific goal.

Results: Twenty patients were included (median age, 6 years; range, 2-16). Six patients aged 3-16 years fulfilled the patient-specific goal. Quality of heart rate recording was good during 3992 of 6576 (61%) hours studied and poor during 300 (5%) hours, and no data was recorded during 2284 (35%) hours. Eighteen of 20 participants indicated that this WD is acceptable to measure vital signs in children under chemotherapy.

Conclusion: The predefined feasibility criterion was not fulfilled. This was mainly due to important compliance problems and independent of the WD itself. However, continuous recording of vital signs was possible across a very wide age range in pediatric patients undergoing chemotherapy for cancer. We recommend to study feasibility in the Everion® again, plus in further WDs, applying measures to enhance compliance.

Trial registration: ClinicalTrials.gov (NCT04134429) on October 22, 2019.

Keywords: Continuous recording; Pediatric oncology; Recording vital signs; Supportive care; Wearable device.

Conflict of interest statement

Jochen Roessler reports personal fees from Pierre Fabre, Roche, Novartis, SOBI, Bayer, Jazz Pharmaceutical and Servier, all outside the submitted work. The other authors declare no competing interests.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
The Everion® device, placed on the upper leg of a 10-month-old and on the upper arm of a 3-year-old child. (Parents gave informed consent for publication of these photographs)
Fig. 2
Fig. 2
a Primary outcome measure—recording of heart rate. b Recording of heart rate variability. Legend: green, good data quality; red, poor data quality; white, no data recorded; gray, no study days; days ≥18 h, number of days with at least 18 hours of good data quality per patient; ID, patient ID
Fig. 3
Fig. 3
Histogram and quality assignment of heart rate, plus proportion of time with poor quality assignment of heart rate variability according to heart rate
Fig. 4
Fig. 4
Histogram and quality assignment of respiration rate. Legend: green, good data quality; red, poor data quality
Fig. 5
Fig. 5
Histogram and quality assignment of core temperature (calculated). Legend: green, good data quality; red, poor data quality

References

    1. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 Update. J Clin Oncol. 2017;35(18):2082–2094. doi: 10.1200/JCO.2016.71.7017.
    1. Fletcher M, Hodgkiss H, Zhang S, Browning R, Hadden C, Hoffman T, Winick N, McCavit TL. Prompt administration of antibiotics is associated with improved outcomes in febrile neutropenia in children with cancer. Pediatr Blood Cancer. 2013;60(8):1299–1306. doi: 10.1002/pbc.24485.
    1. Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58(7):3799–3803. doi: 10.1128/AAC.02561-14.
    1. Salstrom JL, Coughlin RL, Pool K, Bojan M, Mediavilla C, Schwent W, Rannie M, Law D, Finnerty M, Hilden J. Pediatric patients who receive antibiotics for fever and neutropenia in less than 60 min have decreased intensive care needs. Pediatr Blood Cancer. 2015;62(5):807–815. doi: 10.1002/pbc.25435.
    1. Koenig C, Schneider C, Morgan JE, Ammann RA, Sung L, Phillips B. Association of time to antibiotics and clinical outcomes in patients with fever and neutropenia during chemotherapy for cancer: a systematic review. Support Care Cancer. 2020;28(3):1369–1384. doi: 10.1007/s00520-019-04961-4.
    1. Phillips RS, Lehrnbecher T, Alexander S, Sung L. Updated systematic review and meta-analysis of the performance of risk prediction rules in children and young people with febrile neutropenia. PLoS One. 2012;7(5):e38300. doi: 10.1371/journal.pone.0038300.
    1. Delebarre M, Macher E, Mazingue F, Martinot A, Dubos F. Which decision rules meet methodological standards in children with febrile neutropenia? Results of a systematic review and analysis. Pediatr Blood Cancer. 2014;61(10):1786–1791. doi: 10.1002/pbc.2510.
    1. Ammann RA, Bodmer N, Hirt A, Niggli FK, Nadal D, Simon A, Ozsahin H, Kontny U, Kühne T, Popovic MB, Lüthy AR, Aebi C. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study. J Clin Oncol. 2010;28(12):2008–2014. doi: 10.1200/JCO.2009.25.8988.
    1. Witt D, Kellog R, Snyder M, Dunn J. Windows into human health through wearables data analytics. Curr Opin Biomed Eng. 2019;9:28–46. doi: 10.1016/j.cobme.2019.01.001.
    1. Reyzelman AM, Koelewyn K, Murphy M, Shen X, Yu E, Pillai R, Fu J, Scholten HJ, Ma R. Continuous temperature-monitoring socks for home use in patients with diabetes: observational study. J Med Internet Res. 2018;20(12):e12460. doi: 10.2196/12460.
    1. Koshy AN, Sajeev JK, Nerlekar N, Brown AJ, Rajakariar K, Zureik M, Wong MC, Roberts L, Street M, Cooke J, Teh AW. Smart watches for heart rate assessment in atrial arrhythmias. Int J Cardiol. 2018;266:124–127. doi: 10.1016/j.ijcard.2018.02.073.
    1. Noah B, Keller MS, Mosadeghi S, Stein L, Johl S, Delsha S, Tashjian VC, Lew D, Kwan JT, Jusufagic A, Spiegel BMR. Impact of remote patient monitoring on clinical outcomes: an updated meta-analysis of randomized controlled trials. NPJ Digit Med. 2018;15(1):20172. doi: 10.1038/s41746-017-0002-4.
    1. Low CA. Harnessing consumer smartphone and wearable sensors for clinical cancer research. NPJ Digit Med. 2020;3:140. doi: 10.1038/s41746-020-00351-x.
    1. Griffin MP, O'Shea TM, Bissonette EA, Harrell FE, Jr, Lake DE, Moorman JR. Abnormal heart rate characteristics preceding neonatal sepsis and sepsis-like illness. Pediatr Res. 2003;53(6):920–926. doi: 10.1203/01.PDR.0000064904.05313.D2.
    1. Bravi A, Green G, Longtin A, Seely AJE. Monitoring and identification of sepsis development through a composite measure of heart rate variability. PLoS One. 2012;7(9):e45666. doi: 10.1371/journal.pone.0045666.
    1. Ahmad S, Ramsay T, Huebsch L, Flanagan S, McDiarmid S, Batkin I, McIntyre L, Sundaresan SR, Maziak DE, Shamji FM, Hebert P, Fergusson D, Tinmouth A, Seely AJE. Continuous multi-parameter heart rate variability analysis heralds onset of sepsis in adults. PLoS One. 2009;4(8):e6642. doi: 10.1371/journal.pone.0006642.
    1. Mishra T, Wang M, Metwally AA, Bogu GK, Brooks AW, Bahmani A, Alavi A, Celli A, Higgs E, Dagan-Rosenfeld O, Fay B, Kirkpatrick S, Kellogg R, Gibson M, Wang T, Hunting EM, Mamic P, Ganz AB, Rolnik B, Li X, Snyder MP. Pre-symptomatic detection of COVID-19 from smartwatch data. Nat Biomed Eng. 2020;4(12):1208–1220. doi: 10.1038/s41551-020-00640-6.
    1. Natarajan A, Su HW, Heneghan C. Assessment of physiological signs associated with COVID-19 measured using wearable devices. NPJ Digit Med. 2020;3(1):156. doi: 10.1038/s41746-020-00363-7.
    1. Quer G, Radin JM, Gadaleta M, Baca-Motes K, Ariniello L, Ramos E, Kheterpal V, Topol EJ, Steinhubl SR (2021) Wearable sensor data and self-reported symptoms for COVID-19 detection. 27(1):73–77. 10.1038/s41591-020-1123-x
    1. Sampson M, Hickey V, Huber J, Alonso PB, Davies SM, Dandoy CE. Feasibility of continuous temperature monitoring in pediatric immunocompromised patients: a pilot study. Pediatr Blood Cancer. 2019;66(6):e27723. doi: 10.1002/pbc.27723.
    1. Kakarmath SS, de Redon E, Centi AJ, Palacholla R, Kvedar J, Jethwani K, Agboola S. Assessing the usability of an automated continuous temperature monitoring device (iThermonitor) in pediatric patients: non-randomized pilot study. JMIR Pediatr Parent. 2018;1(2):e10804. doi: 10.2196/10804.
    1. Brack E, Koenig C, Roessler J, Ammann RA (2020) Continuous monitoring of health data with a wearable device in pediatric patients undergoing chemotherapy for cancer – a feasibility pilot study. Protoc Exch. 10.21203/rs.3.pex-1321/v1
    1. World Medical Association (2013) Declaration of Helsinki. . Accessed 30 Nov 2020
    1. Biofourmis AG. Everion monitor. . Accessed 30 Nov 2020
    1. Biofourmis Ag. Heart Rate Variability. . Accessed 30 Nov 2020
    1. Dawson ME, Schell AM, Filion DL. Handbook of psychophysiology. 4. New York: Cambridge University Press; 2017. The electrodermal system; pp. 217–243.
    1. Biofourmis AG. Electrodermal activity / Galvanic skin response. . Accessed 30 Nov 2020
    1. Biofourmis AG. Behaviour Metrics. . Accessed 30 Nov 2020
    1. R Core Team (2014) R: A language and environment for statistical computing. Vienna. . Accessed 30 Nov 2020
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124(6):869–871. doi: 10.1001/archderm.124.6.869.
    1. Koenig C, Bodmer N, Agyeman PKA, Niggli F, Adam C, Ansari M, Eisenreich B, Keller N, Leibundgut K, Nadal D, Roessler J, Scheinemann K, Simon A, Teuffel O, von der Weid NX, Zeller M, Zimmermann K, Ammann RA. 39.0°C versus 38.5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial. Lancet Child Adolesc Health. 2020;4(7):495–502. doi: 10.1016/S2352-4642(20)30092-4.
    1. Faulkner L. Beyond the five-user assumption: benefits of increased sample sizes in usability testing. Behav Res Methods Instrum Comput. 2003;35(3):379–383. doi: 10.3758/bf03195514.
    1. Brazendale K, Decker L, Hunt ET, Perry MW, Brazendale AB, Weaver RG, Beets MW. Validity and wearability of consumer-based fitness trackers in free-living children. Int J Exerc Sci. 2019;12(5):471–482.
    1. Duncan MJ, Roscoe CMP, Faghy M, Tallis J, Eyre ELJ. Estimating physical activity in children aged 8-11 years using accelerometry: contributions from fundamental movement skills and different accelerometer placements. Front Physiol. 2019;10:242. doi: 10.3389/fphys.2019.00242.
    1. Price L, Wyatt K, Lloyd J, Abraham C, Creanor S, Dean S, Hillsdon M. Children's compliance with wrist-worn accelerometry within a cluster-randomized controlled trial: findings from the healthy lifestyles programme. Pediatr Exerc Sci. 2018;30(2):281–287. doi: 10.1123/pes.2017-0179.
    1. Winter C, Muller C, Brandes M, Brinkmann A, Hoffmann C, Hardes J, Gosheger G, Boos J, Rosenbaum D. Level of activity in children undergoing cancer treatment. Pediatr Blood Cancer. 2009;53(3):438–443. doi: 10.1002/pbc.22055.
    1. Aznar S, Webster AL, San Juan AF, Chamorro-Viña C, Maté-Muñoz JL, Moral S, Pérez M, García-Castro J, Ramírez M, Madero L, Lucia A. Physical activity during treatment in children with leukemia: a pilot study. Appl Physiol Nutr Metab. 2006;31(4):407–413. doi: 10.1139/h06-014.
    1. Braam KI, van Dijk-Lokkart EM, Kaspers GJL, Takken T, Huisman J, Bierings MB, Merks JHM, van de Heuvel-Eibrink MM, van Dulmen-den Broeder E, Veening MA. Cardiorespiratory fitness and physical activity in children with cancer. Support Care Cancer. 2016;24(5):2259–2268. doi: 10.1007/s00520-015-2993-1.
    1. Hooke MC, Gilchrist L, Tanner L, Hart N, Withycombe JS. Use of a fitness tracker to promote physical activity in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63(4):684–689. doi: 10.1002/pbc.25860.
    1. Bruno E, Biondi A, Bottcher S, Lees S, Schulze-Bonhage A, Richardson MP. Day and night comfort and stability on the body of four wearable devices for seizure detection: a direct user-experience. Epilepsy Behav. 2020;112:107478. doi: 10.1016/j.yebeh.2020.107478.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj